TaperCommunityduloxetine
Boxed Warning
Suicidality risk in children, adolescents, and young adults under 25 during initial treatment.
Duloxetine is an SNRI approved for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain. It is known for a difficult discontinuation syndrome.
20mg, 30mg, 60mg, 120mg
Delayed-release capsules: 20mg, 30mg, 60mg
Category C (risk cannot be ruled out)
Potent inhibitor of both serotonin and norepinephrine reuptake (SNRI). Unlike venlafaxine, it inhibits both transporters at standard therapeutic doses. Weak inhibitor of dopamine reuptake.
Capsules contain enteric-coated pellets. Bead counting possible but pellets are very small.
Bead counting from capsules for gradual reduction. Some pharmacies can compound liquid formulation.
Evidence-based phased reduction schedule. Always taper under medical supervision.
| Phase | Duration | Notes |
|---|---|---|
| Initial reductions | 4-6 weeks | Use available capsule strengths. Withdrawal symptoms often first appear in this phase. |
| Middle reductions | 6-8 weeks | Ask your prescriber about pellet counting or compounded formulations for more gradual adjustments. |
| Lower dose reductions | 8-10 weeks | Compounding pharmacies can prepare suspensions. Discuss options with your prescriber. |
| Final reductions | 8-12 weeks | Very gradual approach needed. Work closely with your prescriber — do not rush this phase. |
1-2 days after dose reduction
3-5 days
2-4 weeks for most symptoms
Brain zaps, nausea, and cognitive fog may persist 2-4 months. Cymbalta discontinuation lawsuits have documented the severity of its withdrawal.
Practical insights shared by members tapering Cymbalta. Not medical advice — always consult your prescriber.
Toxicity
Serotonin syndrome with serotonergic combinations. Hepatotoxicity rare but reported. Severe discontinuation syndrome. Avoid in hepatic impairment and heavy alcohol use.
Pharmacokinetics
Well absorbed, but enteric coating delays absorption (Tmax 6 hours). Bioavailability ~50% (range 32–80%). Food delays Tmax by 6–10 hours and reduces AUC slightly.
~1640 L (~23 L/kg)
Extensively metabolized hepatically via CYP1A2 (primary) and CYP2D6. Numerous metabolites, none pharmacologically active.
Renal (~70% as metabolites, <1% unchanged) and fecal (~20%).
>90% (primarily albumin and alpha-1-acid glycoprotein)
~114 L/hr (apparent oral clearance)
Browse our map of deprescribing-informed providers worldwide.